Semorinemab

Semorinemab · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Semorinemab, covering 2022-03-16 to 2022-10-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Semorinemab in Patients With Moderate Alzheimer's Disease [Phase 2]